A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.

Sally L George, Elisa Izquierdo, James Campbell, Eleni Koutroumanidou, Paula Proszek, Sabri Jamal, Deborah Hughes, Lina Yuan, Lynley V Marshall, Fernando Carceller, Julia C Chisholm, Sucheta Vaidya, Henry Mandeville, Paola Angelini, Ajla Wasti, Tomas Bexelius, Khin Thway, Susanne A. Gatz, Matthew Clarke, Bissan Al-LazikaniGiuseppe Barone, John Anderson, Deborah A. Tweddle, David Gonzalez, Brian A Walker, Jack Barton, Sarita Depani, Jessica Eze, Saira W Ahmed, Lucas Moreno, Andrew Pearson, Janet Shipley, Chris Jones, Darren Hargrave, Tom S Jacques, Michael Hubank, Louis Chesler

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

BACKGROUND:
For children with cancer, the clinical integration of precision medicine to enable predictive biomarker-based therapeutic stratification is urgently needed.

METHODS:
We have developed a hybrid-capture next-generation sequencing (NGS) panel, specifically designed to detect genetic alterations in paediatric solid tumours, which gives reliable results from as little as 50 ng of DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue. In this study, we offered an NGS panel, with clinical reporting via a molecular tumour board for children with solid tumours. Furthermore, for a cohort of 12 patients, we used a circulating tumour DNA (ctDNA)-specific panel to sequence ctDNA from matched plasma samples and compared plasma and tumour findings.

RESULTS:
A total of 255 samples were submitted from 223 patients for the NGS panel. Using FFPE tissue, 82% of all submitted samples passed quality control for clinical reporting. At least one genetic alteration was detected in 70% of sequenced samples. The overall detection rate of clinically actionable alterations, defined by modified OncoKB criteria, for all sequenced samples was 51%. A total of 8 patients were sequenced at different stages of treatment. In 6 of these, there were differences in the genetic alterations detected between time points. Sequencing of matched ctDNA in a cohort of extracranial paediatric solid tumours also identified a high detection rate of somatic alterations in plasma.

CONCLUSION:
We demonstrate that tailored clinical molecular profiling of both tumour DNA and plasma-derived ctDNA is feasible for children with solid tumours. Furthermore, we show that a targeted NGS panel-based approach can identify actionable genetic alterations in a high proportion of patients.
Original languageEnglish
Number of pages12
JournalEuropean Journal of Cancer
Publication statusPublished - 11 Sep 2019

Keywords

  • Circulating tumour DNA
  • Clinical targeted sequencing
  • Paediatric oncology
  • Personalised medicine

Fingerprint

Dive into the research topics of 'A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.'. Together they form a unique fingerprint.

Cite this